Pediapharm Announces Global Exclusive Licensing Agreement for Relaxa(R), an Established Canadian Product With Existing Revenues - Seite 2

"With this acquisition, we are able to reach our objective to accelerate our growth with an accretive transaction through a very favorable transaction structure", said Benoît Hébert, Pediapharm's Vice-President of Business Development and Licensing. "This provides us with some financial flexibility for our upcoming product launches while providing us with the flexibility to complete the outright acquisition of the product rights if and when needed. This is certainly a transaction structure we hope to replicate in the near future."

About Relaxa^®

Relaxa^® is a laxative composed of polyethylene glycol 3350 (PEG 3350). It is indicated for the treatment of occasional constipation in adults (≥ 18 years). Relaxa^® is available in jars of 510g and in boxes of 30 individual 17g sachets. PEG 3350 has the strongest peer-reviewed medical evidence for short-term and longer-term effectiveness compared to other laxatives. For more information, visit www.relaxa.ca.

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; rupatadine, a novel prescription antihistamine to be launched in the coming months; and a broad pipeline of products under registration.

FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements and other statements that are not historical. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to vary materially from target results and the results or events predicted in these forward-looking statements. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. Forward looking statements or information in this news release may include, but are not limited to, business plans and expectations, anticipated benefits from the licensing agreement and Pediapharm's expected financial position.